Heterologous Polyketide Synthase Foldases for Aromatic Compound Libraries
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biosynthetic pathways lack the flexibility and predictability to produce a wide range of aromatic and cyclic compounds, particularly those with specific carbon chain lengths and structures, which are of interest for medicinal and chemical applications.
Innovation Solution
The method involves heterologous co-expression of a Type III polyketide synthase and one or more 'small molecule foldases' from different genera in a recombinant host cell, allowing for the conversion of non-reduced polyketides into aromatic and cyclic compounds of varying lengths and structures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If traditional biosynthetic pathways are used, then natural aromatic compounds can be produced, but the system lacks flexibility and predictability to produce compounds with specific carbon chain lengths and structures
Solution Approach 1:
The patent segments the biosynthetic pathway into distinct functional modules: Type III PKS enzymes for polyketide chain assembly, and separate aromatase/cyclase enzymes for structural formation. This modular segmentation allows independent optimization and selection of specific enzymes to achieve desired carbon chain lengths and compound structures, providing both flexibility and predictability.
Solution Approach 2:
The patent employs universal Type III PKS enzymes that can catalyze the formation of polyketides with varying carbon chain lengths by accepting different starter and extender units. These multi-functional enzymes, combined with universal aromatase/cyclase systems, enable the production of diverse aromatic and cyclic compounds from a core set of biosynthetic tools, achieving versatility without sacrificing structural control.
2Adaptability or versatility
If heterologous expression of Type III PKS and aromatase/cyclase is implemented, then programmable production of aromatic and cyclic compounds is enabled, but the device complexity increases
Solution Approach 1:
The patent utilizes the recombinant host cell's endogenous metabolic pathways to supply substrates (acetyl-CoA, malonyl-CoA, methyl-malonyl-CoA) for the heterologously expressed Type III PKS and aromatase/cyclase enzymes. The host cell self-provides the necessary building blocks and cellular machinery for enzyme expression and function, reducing the need for external supplementation and simplifying the overall system despite the heterologous expression requirements.
3Quantity of substance
If substrate availability in host cell is limited, then preferred substrate production is restricted, but alternative substrates may outcompete and produce undesired compounds
Solution Approach 1:
The patent changes the substrate parameters by providing exogenous supplementation of specific starter units (e.g., p-coumaroyl-CoA, feruloyl-CoA, caffeoyl-CoA) and extender units (e.g., malonyl-CoA, methyl-malonyl-CoA) to the recombinant host cell culture. This parameter adjustment ensures that the Type III PKS enzymes have access to the specific substrates needed to produce desired polyketide chain lengths and aromatic compound structures, preventing substrate limitation and off-target product formation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the programmable production of libraries of aromatic and cyclic compounds with specific carbon chain lengths, offering a significant advancement in biosynthetic capabilities beyond natural systems, allowing for the creation of diverse compounds with potential medicinal and chemical applications.
Implementation Method 1
All PKSs share the ability to catalyze Claisen condensation based fusion of acyl groups by the formation of carbon-carbon bonds coupled with the release of carbon dioxide.
Implementation Method 2
The linear polyketide is then converted in vivo into an aromatic compound of interest by the action of the one or more heterologously-expressed 'small molecule foldases'.
Data Source
AI summary
A method for producing individual or libraries of tri- to pentadecaketide-derived aromatic compounds of interest by heterologous expression of polyketide synthase and aromatase/cyclase in a recombinant host cell.